Skip to main content
. 2011 May;30(5):327–335. doi: 10.5732/cjc.010.10507

Table 5. Summary of adverse events experienced by at least 10% of 52 patients treated with lapatinib plus capecitabine.

Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Total
PPE 25 (48.1) 6 (11.5) 0 0 31 (59.6)
Diarrhea 20 (38.5) 4 (7.7) 0 0 25 (48.1)a
Rash 22 (42.3) 1 (1.9) 2 (3.8) 0 25 (48.1)
Hyperbilirubinemia 4 (7.7) 12 (23.1) 2 (3.8) 0 18 (34.6)
Fatigue 11 (21.2) 4 (7.7) 1 (1.9) 0 16 (30.8)
Nausea 9 (17.3) 1 (1.9) 0 0 10 (19.2)
Neutropenia 0 4 (7.7) 1 (1.9) 2 (3.8) 7 (13.5)

Data are presented as number of patients, with the percentage in parentheses.

aThe grade of diarrhea for one patient (1.9%) was unknown.

PPE, palmar-plantar erythrodysesthesia.